1H26 Attributable NP Robust
发布时间:2026-08-09 来源:华泰证券
For 1H26, Jafron Biomedical (Jafron) posted revenue/attributable NP of RMB1,032/382mn (-9.0/-2.0% YoY), with 2Q26 revenue/attributable NP of RMB472/161mn (-19.6/-19.7% YoY). Affected by external factors such as industry demand fluctuations and intensified market competition, the company’s profit
faced short-term pressure. Considering the continued increase in hemoperfusion therapy penetration, further strengthening of the company’s product academic promotion, coupled with continued overseas market expansion, we are positive on the company’s medium- to long-term growth prospects. Maintain BUY.
GPM declined YoY, impact of price cuts materializing
The company’s 1H26 gross margin was 78.5% (-1.4pp YoY). We estimate that this was because the company proactively lowered the price of KHA130 products in 4Q25, exerting short-term pressure on the gross margin. In 1H26, the company’s sales/G&A/R&D expense ratios were 15.7/6.9/10.0%, changing by -6.3/+0.2/+1.4pp YoY. Among these, the sales-expense ratio declined notably YoY, primarily due to the company’s optimization of organizational structure and strengthened expense control, achieving cost reduction and efficiency gains.
Broad space for star products in the medium to long term
The company’s hemoperfusion devices recorded revenue of RMB868mn in 1H26 (-10.0% YoY). Short-term pressure stems from the price cut of KHA130 products. We are positive on the sector’s medium- to long-term development trajectory, mainly due to: 1) continued ramp-up of new products—KHA series products have now covered more than 1,000 hospitals. In 1H26, they recorded revenue of RMB157mn (+96.6% YoY) and a sales volume of 647,000 units (+299.7% YoY), accounting for 15.23% of the company’s total revenue, up by 8.18pp YoY. 2) Broad hospital coverage: As of end-2025, the company’s nephrology products covered more than 6,000 hospitals in China. 3) High clinical recognition: In recent years, multiple industry expert consensuses and clinical practice guidelines have been released or revised, further enhancing the clinical recognition of the company’s nephrology and hepatology hemoperfusion products.
Expanding business scope to foster new growth curves
1) New regions: Jafron recorded overseas revenue of RMB41.55mn in 1H26 (+20.4% YoY). So far, the company’s products have been sold to 101 countries, with clinical application in more than 2,000 overseas hospitals. Jafron continues to deepen its overseas market presence, formulating different market promotion strategies based on real conditions of different countries, and focusing on channel expansion, collectively achieving YoY growth in overseas revenue. 2) New fields: In addition to nephrology treatment, Jafron has expanded into new fields such as hepatology and acute and critical care in recent years. As of end-2025, the company’s acute and critical care products had covered more than 1,800 hospitals in China, and the company’s self-developed CA series, the first domestic cytokine adsorption column, has covered nearly 230 domestic hospitals.
Earnings forecasts and valuation
Considering the rapid sales volume growth after the price cut of KHA series products, coupled with Jafron’s continued cost reduction and efficiency gains as well as overseas and new business expansion, Jafron’s short-term earnings pressure could ease. We maintain our earnings forecasts, estimating the company’s 2026/2027/2028 attributable NP at RMB645/718/789mn, growing by 21.1/11.2/9.9% YoY. The company is a domestic leader in the hemoperfusion industry, with solid core technology and improving domestic and overseas sales networks. We apply 30x 2026E PE (vs its comparable companies’ average of 22x on Wind consensus) and maintain our target price of RMB24.23.
Risks: Core product sales miss our expectations, price cuts in product tenders.